DBV Technologies Announces 2016 Financial Calendar
(Thomson Reuters ONE) -
Press Release
Montrouge, France, January 8, 2016
DBV Technologies Announces 2016 Financial Calendar
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced its
financial calendar for 2016:
* February 15, 2016 - 2015 cash position as of December 31, 2015
* April 7, 2016 - 2015 full year results
* April 29, 2016 - first three months of 2016 cash position
* June 21, 2016 - Annual General Meeting
* July 28, 2016 - 2016 first half results
* November 3, 2016 - nine months of 2016 cash position
About DBV Technologies
DBV Technologies created the Viaskin® patch, a proprietary technology platform
with broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin while avoiding
compound transfer to the blood. With this new class of self-administered and
non-invasive product candidates, the company is dedicated to safely transforming
the care of food allergy patients, for which there are currently no approved
treatments. DBV's food allergy programs include ongoing clinical studies with
Viaskin Peanut and Viaskin Milk, one experimental program with Viaskin Egg and a
human proof concept clinical study in Eosinophilic Esophagitis. DBV is also
exploring platform indications in vaccines, and selected immune diseases with
unmet medical needs.
DBV Technologies has global headquarters in Paris, France and New York, NY, USA.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. The Company's product candidates have not been approved for sale
in any jurisdiction. Among the factors that could cause actual results to differ
materially from those described or projected herein are uncertainties associated
generally with research and development, clinical trials and related regulatory
reviews and approvals, the risk that historical preclinical results may not be
predictive of future clinical trial results, and the risk that historical
clinical trial results may not be predictive of future trial results. A further
list and description of these risks, uncertainties and other risks can be found
in the Company's regulatory filings with the French Autorité des Marchés
Financiers, the Company's Securities and Exchange Commission filings and
reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2014 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information, future
events or circumstances or otherwise.
DBV Technologies Contacts
Nathalie Donne Susanna Mesa
Director, Corporate Communication & VP Finance, US Investor Relations &
Business Development Strategy
Tél. : +33(0)1 55 42 78 72 Tél. : +1 212-271-0861
nathalie.donne(at)dbv-technologies.com susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tél. : +1-212-223-4017 Tél. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/1977539/724003.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1977539]
Unternehmensinformation / Kurzprofil:
Datum: 08.01.2016 - 07:31 Uhr
Sprache: Deutsch
News-ID 443076
Anzahl Zeichen: 5154
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Announces 2016 Financial Calendar"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
